HUMIRA: a whole different way to treat hidradenitis suppurativa (HS).
While many medicines have played a role in the treatment of HS, HUMIRA is the first and only FDA-approved moderate to severe HS treatment for people 12 years and older.
What you need to know:
Targeting HS from the inside, out.
While the exact cause is unknown, science has shown that HS is a chronic (long-lasting) immune disease.
- With HS, your body produces too much of a protein called TNF-alpha
- This, along with other proteins, leads to increased inflammation
- That inflammation leads to abscesses and/or nodules that may appear underneath or on the surface of your skin
So, it’s active inside your body, but visible on the outside. Because HS may worsen or progress over time, working with a dermatologist to find the right treatment is key.
HUMIRA targets and blocks TNF-alpha, a specific source of inflammation that is thought to contribute to HS symptoms. Many adult HS patients who used HUMIRA in clinical trials experienced significant relief of signs and symptoms.
Significant results in just 3 months.
HUMIRA was studied in over 600 adult patients like you with hidradenitis suppurativa—the largest clinical trial completed for HS to date.
In clinical trials, HUMIRA was proven in many adult patients to reduce the total number of inflammatory nodules and abscesses by at least half without an increase in draining wounds and abscesses in just 3 months. Your results may vary.
A 50% reduction in HS inflammatory nodules and abscesses? It’s possible.
HUMIRA is the #1 prescribed biologic by dermatologists.*
HUMIRA has more than 19 years of clinical trial experience, beginning with moderate to severe rheumatoid arthritis in 1997, with > 100 global clinical studies in safety and efficacy measurement. Worldwide, more than 1 million patients are currently being treated with HUMIRA.†
A dermatologist, a doctor who treats skin diseases, understands the inflammatory component of HS and appropriate ways to treat moderate to severe HS, including HUMIRA. Dermatologists have been prescribing HUMIRA for inflammatory skin diseases (including moderate to severe chronic plaque psoriasis and active psoriatic arthritis) for over 10 years.
*Based on IMS NPA data: Total HUMIRA prescriptions written by dermatologists from 6/6/2014—6/10/2016 vs. Enbrel®, Stelara®, Simponi®, Cimzia®, Otezla®, Cosentyx® and Taltz®. All trademarks are properties of their respective owners.
†As of June, 2016
HUMIRA Use for Rheumatoid Arthritis.
HUMIRA is a prescription medicine used alone, with methotrexate, or with certain other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults, may prevent further damage to your bones and joints, and may help your ability to perform daily activities.
HUMIRA Use for Plaque Psoriasis.
HUMIRA is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
HUMIRA Use for Psoriatic Arthritis.
HUMIRA is a prescription medicine used alone or with certain other medicines to reduce the signs and symptoms of psoriatic arthritis in adults, may prevent further damage to your bones and joints, and may help your ability to perform daily activities.
Preparing for your next appointment?
If you and your dermatologist are talking about moderate to severe hidradenitis suppurativa treatment options, you may want to include HUMIRA in your discussion.
You could get HUMIRA for as little as $5 a month.‡
With the HUMIRA Complete Savings Card, you could pay as little as $5 a month,‡ every month, for your HUMIRA prescription.
†Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.
Ask your doctor about the benefits and risks of HUMIRA.
Talk to your doctor about the benefits and risks of taking a biologic medication like HUMIRA. There are possible risks involved with the use of HUMIRA for the treatment of moderate to severe hidradenitis suppurativa, so it’s important to discuss them with your doctor.
HUMIRA is not right for everyone.
